Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab added to RVd induction and lenalidomide maintenance in newly diagnosed multiple myeloma
2017-004768-37Phase 3Active
- Sponsor
- Heidelberg University
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University. Primary endpoint: Minimal residual disease negativity after induction. Started May 2018; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-004768-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004768-37.